9 completed, 2 terminated. 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Terminated 2 |
Follow Placebo - IV: new trials by email Literature Review of Placebo - IV trials Research Report on Placebo - IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ramucirumab (LY3009806) in Healthy Participants Ramucirumab - IV, Placebo - IV, Ramucirumab - SC - Healthy | Phase 1 | Completed | Eli Lilly and Company | 50 | 2020-07-30 | 2023-02-14 |
| A Study of LY3478006 in Healthy Participants LY3478006 - IV, LY3478006 - SC, Placebo - IV - Healthy | Phase 1 | Terminated | Eli Lilly and Company | 4 | 2020-02-17 | 2021-12-06 |
| A Study of Mirikizumab in Healthy Chinese Participants Mirikizumab - IV, Mirikizumab - SC, Placebo - IV - Healthy | Phase 1 | Completed | Eli Lilly and Company | 60 | 2019-12-04 | 2024-01-26 |
| A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis LY3462817 - IV, LY3462817 - SC, Placebo - IV - Psoriasis | Phase 1 | Terminated | Eli Lilly and Company | 30 | 2019-11-20 | 2022-03-15 |
| A Study of LY3475766 in Healthy Participants LY3475766 - IV, LY3475766 - SC, Placebo - IV - Dyslipidemias | Phase 1 | Completed | Eli Lilly and Company | 48 | 2019-09-03 | 2021-04-28 |
| A Study of LY3361237 in Healthy Participants LY3361237 - SC, LY3361237 - IV, Placebo - SC - Healthy | Phase 1 | Completed | Eli Lilly and Company | 64 | 2018-10-26 | 2019-09-04 |
| A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis LY3316531 - IV, LY3316531 - SC, Placebo - IV - Psoriasis | Phase 1 | Completed | Eli Lilly and Company | 63 | 2018-01-30 | 2023-09-21 |
| A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease LY3303560 - IV, Placebo - IV, Florbetapir F 18 - Alzheimer Disease | Phase 1 | Completed | Eli Lilly and Company | 22 | 2017-01-31 | 2023-10-10 |
| A Study of Mirikizumab (LY3074828) in Healthy Participants Mirikizumab - IV, Mirikizumab - SC, Placebo - IV - Healthy | Phase 1 | Completed | Eli Lilly and Company | 51 | 2015-12-02 | 2024-02-08 |
| A Safety Study of Mirikizumab (LY3074828) Mirikizumab- IV, Mirikizumab - SC, Placebo - IV - Psoriasis | Phase 1 | Completed | Eli Lilly and Company | 45 | 2013-10-01 | 2024-07-25 |
| A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women LY2541546 - SC, LY2541546 - IV, Placebo - SC - Healthy | Phase 1 | Completed | Eli Lilly and Company | 59 | 2009-09-01 | 2018-07-18 |
Psoriasis (3) · Alzheimer Disease (1) · Dyslipidemias (1)
United States (9) · Canada (2) · China (1) · Japan (1) · United Kingdom (1)
2016 (1)